478 related articles for article (PubMed ID: 30475990)
1. Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells.
Vengoji R; Ponnusamy MP; Rachagani S; Mahapatra S; Batra SK; Shonka N; Macha MA
Carcinogenesis; 2019 Mar; 40(1):2-14. PubMed ID: 30475990
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
3. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
4. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells.
Würth R; Barbieri F; Florio T
Biomed Res Int; 2014; 2014():126586. PubMed ID: 24527434
[TBL] [Abstract][Full Text] [Related]
5. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.
Triscott J; Rose Pambid M; Dunn SE
Stem Cells; 2015 Apr; 33(4):1042-6. PubMed ID: 25588723
[TBL] [Abstract][Full Text] [Related]
6. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
7. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML
Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616
[TBL] [Abstract][Full Text] [Related]
8. The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells.
Bou-Gharios J; Assi S; Bahmad HF; Kharroubi H; Araji T; Chalhoub RM; Ballout F; Harati H; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):227-239. PubMed ID: 33140310
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme.
Tomuleasa C; Soritau O; Kacso G; Fischer-Fodor E; Cocis A; Ioani H; Timis T; Petrescu M; Cernea D; Virag P; Irimie A; Florian IS
J BUON; 2010; 15(4):758-62. PubMed ID: 21229642
[TBL] [Abstract][Full Text] [Related]
10. Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
Liu YC; Lee IC; Chen PY
J Neurooncol; 2018 May; 137(3):511-522. PubMed ID: 29357090
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
William D; Walther M; Schneider B; Linnebacher M; Classen CF
PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier.
Da Ros M; De Gregorio V; Iorio AL; Giunti L; Guidi M; de Martino M; Genitori L; Sardi I
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30248992
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Chemopredictive Assay for Targeting Cancer Stem Cells in Glioblastoma Patients.
Howard CM; Valluri J; Alberico A; Julien T; Mazagri R; Marsh R; Alastair H; Cortese A; Griswold M; Wang W; Denning K; Brown L; Claudio PP
Transl Oncol; 2017 Apr; 10(2):241-254. PubMed ID: 28199863
[TBL] [Abstract][Full Text] [Related]
15. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
16. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
17. MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties.
Lin JC; Tsai JT; Chao TY; Ma HI; Chien CS; Liu WH
Radiother Oncol; 2018 Nov; 129(2):352-363. PubMed ID: 30322656
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
19. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
[TBL] [Abstract][Full Text] [Related]
20. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
